Search

Displaying results 1031 - 1040 of 4692 in total
  1. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940] By preventing this aberrant signaling, it reduces the formation of new abnormal bone.[L63940] It is administered by intravenous infusion every four weeks. … [L63940] Garetosmab-grts was approved by the FDA on August 19, 2026 to reduce the number of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP.

  2. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.

  3. Drug

    Silver nitrate

    go.drugbank.com/drugs/DB11080
    Approved

    In its solid form, silver nitrate is coordinated in a trigonal planar arrangement. It is often used as a precursor to other silver-containing compounds.

  4. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.

  5. Drug

    Pivmecillinam

    go.drugbank.com/drugs/DB01605
    ApprovedInvestigational

    Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa.

  6. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

  7. Drug

    Trandolapril

    go.drugbank.com/drugs/DB00519
    ApprovedInvestigational

    It is metabolized to its biologically active diacid form, trandolaprilat, in the liver.

  8. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  9. Drug

    Nimodipine

    go.drugbank.com/drugs/DB00393
    ApprovedInvestigational

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.

  10. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730]. … Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).